LeonaBio, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
LeonaBio, Inc. (LONA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $0.16 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2025-02-27
- LeonaBio, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $1.35, a 56.98% increase year-over-year.
- LeonaBio, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2022-03-31 was $0.86, a 22.52% decline year-over-year.
- LeonaBio, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2021-03-31 was $1.11.
- LeonaBio, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $0.16, a 87.60% decline from fiscal 2023.
- LeonaBio, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $1.29, a 25.24% increase from fiscal 2022.
- LeonaBio, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $1.03, a 16.94% decline from fiscal 2021.
- LeonaBio, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2021 was $1.24, a 24.00% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.16 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $0.16 10-Q · filed 2024-11-07 | |||
| 2023-12-31 | $1.29 10-K · filed 2024-02-22 | |||
| 2023-09-30 | $1.35 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $1.35 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $1.35 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | $1.03 10-K · filed 2023-03-23 | |||
| 2022-09-30 | $1.02 10-Q · filed 2022-11-10 | |||
| 2022-06-30 | $1.02 10-Q · filed 2022-08-15 | |||
| 2022-03-31 | $0.86 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $1.24 10-K · filed 2022-03-28 | |||
| 2021-09-30 | $1.29 10-Q · filed 2021-11-10 | |||
| 2021-06-30 | $1.27 10-Q · filed 2021-08-16 | |||
| 2021-03-31 | $1.11 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | $1.00 10-K · filed 2021-03-25 | |||
| 2020-09-30 | $1.00 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |